Telephos Inteligence
Qormi, Malta
Telephos Intelligence solves high placebo response rates in CNS trials. This ""billion-dollar risk"" forces larger sample sizes (+100-200 patients) , inflating budgets by ~$8.4M. Total Phase III failure costs reach $800M-$1.4B per program. It also addresses low rater reliability; an ICC drop from 0.90 to 0.70 mandates a 22% sample size increase. 45% of development time adds no clinical value. Finally, it slashes inter-rater variability by 40-60%, enabling smaller, more precise, and cheaper trials.
Only accessible to MedStartr community members.
Join nowCompany Info
- Founded
- 2026
- Website
- telephos-hello-world.lovable.app
Only accessible to MedStartr community members.
Join nowWhat do you think of Telephos Inteligence?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.
Only accessible to MedStartr community members.
Join now